SK bioscience Co.,Ltd. (KRX:302440)
South Korea flag South Korea · Delayed Price · Currency is KRW
43,150
+500 (1.17%)
Mar 27, 2026, 3:19 PM KST

Revenue by Segment

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
FY 2023FY 2022FY 2021
Period Ending
Dec '23 Dec '22 Dec '21
Pharmaceuticals
369.51B456.73B929.00B
Pharmaceuticals Growth
-19.10%-50.84%-
Total
369.51B456.73B929.00B
Total Growth
-19.10%-50.84%-

Revenue by Geography

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
FY 2023FY 2022FY 2021
Period Ending
Dec '23 Dec '22 Dec '21
South Korea
158.22B224.16B695.86B
South Korea Growth
-29.42%-67.79%-
America
185.96B217.83B48.41B
America Growth
-14.63%349.99%-
Europe
21.20B13.78B184.50B
Europe Growth
53.88%-92.53%-
Asia
3.89B651.33M233.27M
Asia Growth
497.76%179.22%-
Middle East
231.61M305.04M-
Middle East Growth
-24.07%--
Total
369.51B456.73B929.00B
Total Growth
-19.10%-50.84%-
Source: S&P Global Market Intelligence.